Bayer launches Yaz in Europe; Teva sues Sandoz over Copaxone;

> Bayer is launching its low-dose contraceptive pill Yaz in Europe this month, the company said. Bayer Release

> Teva Pharmaceutical Industries has sued Sandoz, the generic subsidiary of Novartis, and Momenta for allegedly infringing the patents on the multiple sclerosis drug Copaxone. Report

> SAFC Pharma, a pharmaceutical products subsidiary of Sigma-Aldrich Corp., has announced plans for a $30 million expansion of its Madison, Wisc., operations. Report

> Ortho Biotech announced the European Commission's approval of Velcade for some patients with previously untreated multiple myeloma, in combination with melphalan and prednisone. Ortho Release

> India's Aurobindo Pharms received tentative FDA approval to manufacture and market Abacavir Sulfate, its version of GlaxoSmithKline's HIV treatment Lamivudine. Report

> Alembic, India's oldest pharmaceutical company, is planning to double its turnover in the next two to three years by foraying into the regulated markets of the US and Europe as well as contract manufacturing, a company director said. Report

> Perrigo said it acquired the exclusive U.S. rights to sell and distribute levocetirizine tablets, the generic version of UCB's Xyzal tablets, from Synthon Pharmaceuticals Inc. Report

> Biovail got Canadian regulators' nod for an expanded indication for once-daily Ralivia to include the treatment of moderately severe pain in addition to moderate pain. Report

> Philanthropists Eli and Edythe Broad announced plans to donate a massive $400 million for genetic research at the Broad Institute. Report

> The FDA is taking a critical look at Pfizer and Ligand's Fablyn, an osteoporosis drug the companies developed together that has been submitted to the FDA. Report

> With a $500 million investment, Brno--the second-largest city in the Czech Republic--hopes to appeal to the biotech sector and establish a reputation as a major European research hub. Report

> Abraxis has signed a $295M licensing deal with ProMetic Life Sciences to develop and market four biotech drugs. Report

> BIO--the industry's trade organization--isn't supporting a particular candidate in this coming election. Why? Because no matter who wins, the industry can look forward to a level of support it hasn't experienced in the last eight years. Report

Emerging Drug Developer: Acucela

And Finally... People who sweat heavily during exercise are less likely to develop asthma, a new study shows. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.